Pretransplant malignancy in pediatrics is not a risk factor for renal graft failure

Abstract

AbstractBackgroundIn adults, pretransplant malignancy (PTM) negatively impacts patient survival due to immunosuppression regimens influencing post‐transplantation tumor growth. Few reports investigate the outcomes of pediatric kidney transplantation with PTM. We compare transplant outcomes for pediatric patients with PTM to matched controls, including cancer types extending beyond Wilms tumor.MethodsThe United Network of Organ Sharing Database was queried to identify pediatric transplant recipients with histories of PTM. All PTM patients were matched to non‐PTM patients, at a 1:1 ratio, with 0.001 match tolerance. Matching variables included transplant year, recipient age, recipient gender, recipient race, donor type, and prior transplant. Death‐censored graft and patient survival were analyzed. All statistics were reported with 95% confidence intervals (CI).ResultsAfter propensity matching, 285 PTM and 285 non‐PTM patients were identified, with transplant dates from 1990 to 2020. Median Kidney Donor Profile Index values were comparable between cohorts, 17% and 12%, respectively (p = .065). Kaplan–Meier analysis revealed that PTM patients did not have a significantly different rate of death‐censored graft failure, compared to the non‐PTM group [HR 0.76; 95% CI (0.54–1.1)]. There was also no difference in the overall survival between the two groups of patients [HR 1.1; 95% CI (0.66–2.0)].ConclusionA history of pediatric malignancy has minimal independent effect on their post‐transplant survival. Additionally, pediatric patients with PTM demonstrated equivalent rates of graft survival. Thus, in contrast to adults, renal failure in children with history of pediatric malignancies should not be considered a complicating factor for renal transplantation.